

Hypertrophic Cardiomyopathy

The Therapeutic Role of
Calcium Antagonists

Edited by
M. Kaltenbach and S. E. Epstein

Hypertrophic Cardiomyopathy

The Therapeutic Role of
Calcium Antagonists

Edited by
M. Kaltenbach and S. E. Epstein

With 172-Figures

Springer-Verlag
Berlin Heidelberg New York 1982

Professor Dr. med. M. KALTENBACH, Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-von-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt 70

S. E. EPSTEIN, M. D., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA

ISBN 3-540-11065-8 Springer-Verlag Berlin Heidelberg New York
ISBN 0-387-11065-8 Springer-Verlag New York Heidelberg Berlin

Library of Congress Cataloging in Publication Data. Main entry under title: Hypertrophic cardiomyopathy. Bibliography: p. Includes index. 1. Heart-Hypertrophy-Chemotherapy. 2. Verapamil. 3. Calcium-Antagonists-Therapeutic use. I. Kaltenbach, Martin. II. Epstein, S. E. (Stephen E.) [DNLM: 1. Myocardia diseases-Drug therapy. 2. Calcium-Antagonists and inhibitors. 3. Iproveratril-Therapeutic use. WG 280 H998] RC685.H9H957. 616.1'24. 81-16665. ISBN 0-387-11065-8 (U.S.). AACR2

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1982

Printed in Germany.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Typesetting, printing, and bookbinding: Konrad Tritsch, Graphischer Betrieb, 8700 Würzburg
2127/3130-543210

Preface

First described in 1907 by Schicke but recognized as a clinical entity only as recently as 1958, when Teare published the pathologic findings in patients with hypertrophic cardiomyopathy (HCM), an explosion of knowledge about this fascinating disease has occurred, which has caused a profound evolution of our understanding of its broad pathophysiologic and clinical spectrum. Progress has been particularly rapid in the past few years when M-mode echocardiography, and more recently 2-dimensional echocardiography have been applied to the study of HCM.

In addition to new insights as to what the disease is, there has been enormous progress concerning its treatment, with the application of beta-adrenergic blocking agents and surgical relief of left ventricular outflow tract obstruction. Although these approaches have led to great strides in the symptomatic control of the disease, many patients' symptoms have remained refractory to medical and surgical therapy. Most discouragingly, sudden death still occurs, even in patients on large doses of beta-blocking agents and in patients who have had surgical relief of left ventricular outflow tract obstruction.

Therapy of HCM with calcium antagonists was initiated in 1973 in Frankfurt/Main. Independently, several years later, the group in Bethesda started with the same therapeutical approach. Many assumptions had to be made to justify this new form of treatment, e.g.:

- High doses of verapamil can be given over a long period of time without severe side effects
- Cardiomyopathy or its clinical effects relates to calcium ion overload or increased intramyocardial availability of calcium
- The negative inotropic action of verapamil is not of major clinical importance.

In the meantime our understanding of the disease as well as of the basic principle of calcium antagonism as defined by Fleckenstein has considerably increased. Most importantly, therapeutic experience with the use of verapamil in treating patients with HCM has increased markedly, and data relating to its effects have been collected at different institutions throughout the world.

This volume is aimed to represent our up-to-date knowledge of the topic. It offers for the first time an international overview on a new therapeutic approach to HCM.

MARTIN KALTENBACH · STEPHEN E. EPSTEIN

List of Contributors

- BAYER, R., Physiologisches Institut der Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- BECKER, H.-J., Medizinische Klinik I des Stadtkrankenhauses Hanau, Leimenstraße 20, D-6450 Hanau 1
- BIAMINO, G., Medizinische Klinik und Poliklinik, Klinikum Steglitz, Freie Universität Berlin, Hindenburgdamm 30, D-1000 Berlin
- BLEIFELD, W., II. Medizinische Klinik und Poliklinik, Kardiologische Abteilung, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-2000 Hamburg 20
- BLUSCHKE, V., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- BONOW, R. O., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- BUBENHEIMER, P., Benedikt-Kreutz-Rehabilitationszentrum für Herz- und Kreislaufkranke e.V., Südring 15, D-7812 Bad Krozingen
- BUSSMANN, W.-D., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- CONDIT, J. R., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- EICHELBAUM, M., Medizinische Klinik der Universität Bonn, Siegmund-Freud-Str. 25, D-5300 Bonn
- EPSTEIN, S. E., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- FLECKENSTEIN, A., Physiologisches Institut der Universität Freiburg, Hermann-Herder-Straße 7, D-7800 Freiburg i. Br.
- FREY, M., Physiologisches Institut der Universität Freiburg, Hermann-Herder-Str. 7, D-7800 Freiburg i. Br.
- FUSTER, V., Section of Cardiovascular Surgical Research, Mayo Clinic, 200 First Street SW, MN 55901/USA
- GOODWIN, J. F., Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, GB-London W12 OHS

- GOTTDIENER, J. S., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- HANRATH, P., II. Medizinische Klinik und Poliklinik, Kardiologische Abteilung, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-2000 Hamburg 20
- HIRZEL, H. O., Medizinische Poliklinik, Departement für Innere Medizin, Universität Zürich, Rämistraße 100, CH-8091 Zürich
- HOPF, R., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- HÜBNER, K., Zentrum der Pathologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- JENNI, R., Medizinische Poliklinik, Departement für Innere Medizin, Universität Zürich, Rämistraße 100, CH-8091 Zürich
- KALTENBACH, M., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- KAUFMANN, R., Physiologisches Institut der Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- KAYE, M. P., Section of Cardiovascular Surgical Research, Mayo Clinic, 200 First Street SW, Rochester, MS 55901/USA
- KEIDEL, I., Physiologisches Institut der Universität Freiburg, Hermann-Herder-Str. 7, D-7800 Freiburg i. Br.
- KENT, K. M., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- KIRSTEN, R., Abteilung für Klinische Pharmakologie, Klinikum der Johann-Wolfgang-von-Goethe-Universität, Sandhofstraße 74, D-6000 Frankfurt/Main
- KOBER, G., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- KOCH, J.-P., National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- KÖHLER, E., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- KONRAD, A., Medizinische Klinik der Bundesknappschaft, Akademisches Lehrkrankenhaus der Universität des Saarlandes, Lazarettstr. 4 D-6603 Sulzbach
- KRAYENBUEHL, H. P., Medizinische Poliklinik, Departement für Innere Medizin, Universität Zürich, Rämistraße 100, CH-8091 Zürich
- KREMER, P., II. Medizinische Klinik und Poliklinik, Kardiologische Abteilung, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-2000 Hamburg 20

- KÜBLER, W., Abteilung Innere Medizin III, Medizinische Klinik der Universität Heidelberg, Bergheimer Straße 58, D-6900 Heidelberg
- KUHN, H., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- KUNKEL, B., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- LEON, M. B., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- LEUNER, C., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- LIPSON, L. C., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- LIU, S.-K., Departments of Pathology and Medicine, The Animal Medical Center, New York, NY/USA
- LÖSSE, B., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- LOOGEN, F., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- LOSSNITZER, K., Medizinische Klinik der Bundesknappschaft Sulzbach/Saar, Akademisches Lehrkrankenhaus der Universität des Saarlandes, Lazarettstr. 4 D-6603 Sulzbach
- MANNHOLD, R., Physiologisches Institut der Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- MARON, B. J., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- MATHEY, D. G., II. Medizinische Klinik und Poliklinik, Kardiologische Abteilung, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-2000 Hamburg
- MCALLISTER, Jr., R. G., Veterans Administrations Medical Center, Lexington, Kentucky, KY 40507/USA
- MOHR, W., Abteilung Pathologie der Universität Ulm, Oberer Eselsberg, M 23, D-7900 Ulm
- MORROW, A. G., National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- MÜLLER, A., Kerckhoff-Klinik der Max-Planck-Gesellschaft, Benekestraße 6-8, D-6350 Bad Nauheim
- VON OLSHAUSEN, K.-E., Abteilung Innere Medizin III, Medizinische Klinik der Universität Heidelberg, Bergheimer Straße 58, D-6900 Heidelberg
- ROBERTS, W. C., Pathology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA

- RODENKIRCHEN, R., Physiologisches Institut der Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- ROSING, D. R., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20205/USA
- ROSKAMM, H., Benedikt-Kreutz-Rehabilitationszentrum für Herz- und Kreislaufkranke e.V., Südring 15, D-7812 Bad Krozingen
- SCHLEPPER, M., Kerckhoff-Klinik der Max-Planck-Gesellschaft, Benekestraße 6 – 8, D-6350 Bad Nauheim
- SCHMIDT, A., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- SCHNEIDER, M., Zentrum der Pathologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- SCHÖNUNG, W., Kerckhoff-Klinik der Max-Planck-Gesellschaft, Benekestraße 6 – 8, D-6350 Bad Nauheim
- SCHRÖDER, R., Medizinische Klinik und Poliklinik, Klinikum Steglitz, Freie Universität Berlin, Hindenburgdamm 30, D-1000 Berlin 45
- SOMOGYI, A., Medizinische Klinik der Universität Bonn, Siegmund-Freud-Str. 25, D-5300 Bonn
- SONNTAG, F., II. Medizinische Klinik und Poliklinik, Kardiologische Abteilung, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, D-2000 Hamburg 20
- THELEN, U., Medizinische Klinik und Poliklinik, Klinik B (Schwerpunkt Kardiologie), Universität Düsseldorf, Moorenstraße 5, D-4000 Düsseldorf
- TILLEY, L. P., Departments of Pathology and Medicine, The Animal Medical Center, New York, NY/USA
- TROESCH, M. P., Medizinische Poliklinik, Departement für Innere Medizin, Universität Zürich, Rämistraße 100, CH-8091 Zürich
- TROMPLER, A., Zentrum der Inneren Medizin, Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70
- WELLS, D. J., Section of Cardiovascular Surgical Research, Mayo Clinic, 200 First Street SW, Rochester, MS 55901/USA
- WITZKE, D. J., Section of Cardiovascular Surgical Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55901/USA
- WOODCOCK, B. G., Zentrum der Pharmakologie, Abteilung für Klinische Pharmakologie, Klinikum der Johann-Wolfgang-von-Goethe-Universität, Sandhofstraße 74, D-6000 Frankfurt/Main
- ZEBE, H., Abteilung Innere Medizin III, Medizinische Klinik der Universität Heidelberg, Bergheimerstraße 58, D-6900 Heidelberg
- ZEYER, D., Medizinische Klinik der Bundesknappschaft Sulzbach/Saar, Akademisches Lehrkrankenhaus der Universität des Saarlandes, D-6603 Sulzbach

Contents

Clinical and Anatomical Characterization of Hypertrophic Cardiomyopathy

Synopsis. J. F. GOODWIN	3
Hypertrophic Cardiomyopathy: An Overview. S. E. EPSTEIN and B. J. MARON. With 7 Figures	5
Echocardiographic Identification of Patterns of Left Ventricular Hyper- trophy in Hypertrophic Cardiomyopathy. B. J. MARON, J. S. GOTT- DIENER, and S. E. EPSTEIN. With 17 Figures	18
Distribution and Significance of Cardiac Muscle Cell Disorganization in the Left Ventricle of Patients with Hypertrophic Cardiomyopathy: Evidence of a Diffuse Cardiomyopathic Process. B. J. MARON and W. C. ROBERTS. With 12 Figures	38
Left Ventricular Biopsy in Hypertrophic Cardiomyopathy: Light and Electron Microscopic Evaluations. B. KUNKEL, M. SCHNEIDER, R. HOPF, G. KÖBER, K. HÜBNER, and M. KALTENBACH. With 3 Figures	58

Cardiomyopathy in Animals and Therapeutic Interventions

Synopsis. B. J. MARON	72
Spontaneously Occurring Hypertrophic Cardiomyopathy in Dogs and Cats: A Potential Animal Model of a Human Disease. B. J. MARON, S.-K. LIU, and L. P. TILLEY. With 9 Figures	73
Cardiac Effects of Nerve Growth Factor in Dogs. M. P. KAYE, D. J. WITZKE, D. J. WELLS, and V. FUSTER. With 7 Figures	88
Prevention of Myocardial Cell Necrosis in the Syrian Hamster – Results of Long-Term Treatment. K. LOSSNITZER, A. KONRAD, D. ZEYER, and W. MOHR. With 4 Figures	99
Prevention by Verapamil of Isoproterenol-Induced Hypertrophic Cardio- myopathy in Rats. A. FLECKENSTEIN, M. FREY, and J. KEIDEL. With 4 Figures	115

Effects of Acute Administration of Verapamil in Patients with Hypertrophic Cardiomyopathy

Synopsis. S. E. EPSTEIN	122
Acute Hemodynamic Effects of Verapamil in Hypertrophic Cardio- myopathy. D. R. ROSING, K. M. KENT, R. O. BONOW, and S. E. EPSTEIN. With 9 Figures	124

Hemodynamics and Contractility After Oral, Intravenous, and Intracoronary Application of Calcium Antagonists. W.-D. BUSSMANN, R. HOPF, A. TROMPLER, and M. KALTENBACH. With 9 Figures	138
Effect of Verapamil on Left Ventricular Isovolumic Relaxation Time and Regional Left Ventricular Filling in Hypertrophic Cardiomyopathy. P. HANRATH, D. G. MATHEY, P. KREMER, F. SONNTAG, and W. BLEIFELD. With 5 Figures	148

Treatment of Hypertrophic Cardiomyopathy with Verapamil

Synopsis. H. KUHN	160
Verapamil Treatment of Hypertrophic Cardiomyopathy. R. HOPF and M. KALTENBACH. With 13 Figures	163
Volume Parameters of the Heart During Long-Term Verapamil Treatment in Patients with Hypertrophic Cardiomyopathy. M. KALTENBACH and R. HOPF. With 7 Figures	179
Long-Term Clinical Effects of Verapamil in Patients with Hypertrophic Cardiomyopathy. D. R. ROSING, J. R. CONDIT, B. J. MARON, K. M. KENT, M. B. LEON, R. O. BONOW, L. C. LIPSON, and S. E. EPSTEIN. With 4 Figures	187
Effects of Verapamil on Ventricular Wall Thickness of Patients with Hypertrophic Cardiomyopathy. H. O. HIRZEL, M. P. TROESCH, R. JENNI, and H. P. KRAYENBUEHL. With 6 Figures	203
Long-Term Verapamil Treatment in Patients with Hypertrophic Nonobstructive Cardiomyopathy. H. KUHN, U. THELEN, C. LEUNER, E. KÖHLER, V. BLUSCHKE, and F. LOOGEN. With 10 Figures	214
Verapamil: Its Potential for Causing Serious Complications in Patients with Hypertrophic Cardiomyopathy. S. E. EPSTEIN and D. R. ROSING. With 3 Figures	225

Long-Term Results of Different Therapeutic Interventions in Comparison with Verapamil

Synopsis. R. HOPF	236
Efficacy of Operation for Obstructive Hypertrophic Cardiomyopathy: A 20-Year Experience with Ventricular Septal Myotomy and Myectomy. B. J. MARON, J.-P. KOCH, S. E. EPSTEIN, and A. G. MORROW. With 10 Figures	238
Functional Results in Medically and Surgically Treated Patients with Hypertrophic Obstructive Cardiomyopathy. B. LÖSSE, H. KUHN, and F. LOOGEN. With 3 Figures	251
Long-Term Treatment of Hypertrophic Cardiomyopathy with Verapamil or Propranolol. Preliminary Results of a Multicenter Study. G. KOBER, R. HOPF, A. SCHMIDT, M. KALTENBACH, G. BIAMINO, R. SCHRÖDER, P. BUBENHEIMER, H. ROSKAMM, P. HANRATH, F. SONNTAG, K.-E. v. OLSHAUSEN, H. ZEBE, W. KÜBLER, W. SCHÖNUNG, A. MÜLLER, and M. SCHLEPPER. With 3 Figures	261

Effects of Different Calcium Blockers and Implications Regarding Therapy of Hypertrophic Cardiomyopathy

Synopsis. G. KOBER	268
The Antianginal Efficacy of Seven Different Calcium Antagonists. H.-J. BECKER, R. HOPF, G. KOBER, and M. KALTENBACH. With 2 Figures	269
Differentiation of Calcium-Antagonistic Drugs with Respect to Their Myocardial Effects. R. KAUFMANN, R. BAYER, R. RODENKIRCHEN, and R. MANNHOLD. With 4 Figures	276
The Concept of Calcium Antagonist Therapy in Cardiac Hypertrophy. Different Calcium Antagonists with Respect to Therapeutic Efficacy in Hypertrophic Cardiomyopathy. Combined Therapy with Calcium Antagonists and Other Drugs? M. KALTENBACH, G. KOBER, and R. HOPF. With 1 Figure	285

Clinical Pharmacology of Verapamil in Hypertrophic Cardiomyopathy

Synopsis. R. G. McALLISTER, Jr.	290
Pharmacokinetics, Bioavailability, and ECG Response of Verapamil in Man. M. EICHELBAUM and A. SOMOGYI. With 3 Figures	291
Verapamil Plasma Concentrations and Indices of Heart Size in Hyper- trophic Obstructive Cardiomyopathy – Evidence for the Existence of a Therapeutic Range. B. G. WOODCOCK, R. HOPF, and R. KIRSTEN. With 8 Figures	298
Plasma Verapamil Levels in Patients with Hypertrophic Cardiomyopathy: Interpatient Variability and Clinical Usefulness. M. B. LEON, D. R. ROSING, and S. E. EPSTEIN. With 6 Figures	309
Correlation of Verapamil Plasma Levels with Electrocardiographic and Hemodynamic Effects. R. G. McALLISTER, Jr. With 3 Figures	322
Subject Index	332

Clinical and Anatomical Characterization of Hypertrophic Cardiomyopathy

Synopsis

J. F. GOODWIN

Epstein and colleagues comment on terminology (listing 58 names that have been given to hypertrophic cardiomyopathy) and emphasize the importance of abnormalities of diastolic function and reinforce the view that "obstruction" to outflow is only one aspect of this disease. The spectrum of hypertrophic cardiomyopathy is broader than originally suspected.

Echocardiographic studies have shown that hypertrophy can occur in all parts of the ventricle and may be found throughout the length of the ventricular septum, or in its upper or in its lower portions only. Hypertrophy, though usually asymmetrical, can be symmetrical. These variations have led to suggestions that hypertrophic cardiomyopathy is not one but many diseases or is even a nonspecific reaction of the myocardium with hypertrophy. This is not true: Hypertrophic cardiomyopathy is undoubtedly a major disease entity but with many forms and variations.

Sudden death is the most common type of death. Neither hemodynamic nor electrocardiographic findings are helpful in identifying the patient destined to die; nor does any type of ventricular morphology appear to be predictive. However, there may be a trend relating septal thickness to sudden death. A strong family history, young age, and massive cardiomegaly would suggest a poor prognosis, while one subset of hypertrophic cardiomyopathy is the so-called malignant familial type alluded to by Epstein and Maron.

The identification of occult arrhythmias by ambulatory ECG monitoring has greatly added to our knowledge. The experience of Maron and Epstein, supported by our own experience at the Royal Postgraduate Medical School, indicates that ventricular arrhythmias are common, and a direct relationship has been demonstrated between ventricular tachycardia and sudden death.

Cellular disorganization can be found in hypertrophic cardiomyopathy but also in a variety of cardiac diseases and even in healthy persons. In contrast to these cases with only small foci of cellular disorganization, patients with hypertrophic cardiomyopathy show large areas of the ventricular septum and also of the free left ventricular wall with cellular disorganization. It is not the finding itself but the widespread occurrence that is considered characteristic for hypertrophic cardiomyopathy. In the study of Maron et al. the most widespread cellular abnormalities were found in patients dying suddenly without prior functional limitations. It is therefore speculated that widespread cellular disorganization could provide a substrate for malignant ectopy.

The careful studies by Kunkel and colleagues show the value of endomyocardial biopsy in assessing the severity of the disease but less so in making a diagnosis. The patchy nature of the myofibrillar disarray in hypertrophic cardiomyopathy and the presence of similar lesions in other forms of ventricular hypertrophy secondary to

other cardiac disorders make diagnosis by endomyocardial biopsy extremely difficult. It is suggested that the severity of hypertrophy in the biopsy from the left ventricular free wall of patients with hypertrophic cardiomyopathy may provide information concerning the stage and progress of the disease and also the response of the myocardium to the abnormal anatomical and functional situation. Thus, although endomyocardial biopsy may provide additional information about this disease, it should not be used to diagnose hypertrophic cardiomyopathy.

Hypertrophic Cardiomyopathy: An Overview*

STEPHEN E. EPSTEIN and BARRY J. MARON

Hypertrophic cardiomyopathy presents extraordinary challenges to the investigator, partly because of the extreme diversity in its clinical, hemodynamic, and anatomical presentation, and partly because of the rapid changes that have occurred in our understanding of its pathophysiology, natural history, and treatment since it was first recognized as a clinical entity in 1958 [1]. The profound changes that have occurred in our concepts of the disease are reflected in Table 1, which lists the names that have been appended to this entity at one time or another over the years.

The multiplicity of descriptive names given to this disease relate primarily to several factors. First, several centers were involved more or less simultaneously in the pioneering studies that characterized the disease and each, understandably, developed names for this newly discovered clinical entity based on those aspects of the disease that were most impressive to the individual investigators. Second, as additional information accumulated, concepts of the disease changed, with important new insights often leading to new names.

Characteristic Features of Hypertrophic Cardiomyopathy

Initially, this disease was viewed primarily as one characterized by obstruction to left ventricular outflow; hence, the disease acquired such names as "idiopathic hypertrophic subaortic stenosis", or IHSS, [2] "muscular subaortic stenosis" [3], and "hypertrophic obstructive cardiomyopathy", or HOCM [4].

The widespread application of M-mode echocardiography to cardiac diagnosis in the early 1970s confirmed the hypertrophic nature of the disease [5-8]. Echocardiographic studies also demonstrated that outflow obstruction was absent in a large proportion of patients with hypertrophic cardiomyopathy [9], that it was often transmitted as an autosomal dominant trait [9, 10], and that an hypertrophied ventricular septum, measuring at least 1.3 times the thickness of the left ventricular free wall, was invariable. These echocardiographic observations led to the introduction of the term "asymmetric septal hypertrophy" and its acronym "ASH" to describe the disease hypertrophic cardiomyopathy [5]. However, recent observations have indicated the inadequacy of this concept of the disease [11]. In particular, extensive two-dimensional echocardiographic studies [11a, 12], demonstrated that while most of the patients have septal hypertrophy, the majority also have considerable thickening of the left ventricular free wall, which not infrequently is equal to or

* This paper is revised and updated from that published in *Clinical and Investigative Medicine* 3:185-193, 1980

Table 1. Terms used to describe hypertrophic cardiomyopathy

Asymmetrical hypertrophic cardiomyopathy	1972
Asymmetrical hypertrophy of the heart	1958
Asymmetrical septal hypertrophy	1973
Brock's disease	1977
Diffuse muscular subaortic stenosis	1973
Diffuse subvalvular aortic stenosis	1961
Dynamic hypertrophic subaortic stenosis	1971
Dynamic muscular subaortic stenosis	1966
Familial hypertrophic subaortic stenosis	1961
Familial muscular subaortic stenosis	1959
Familial myocardial disease	1967
Functional aortic stenosis	1959
Functional hypertrophic subaortic stenosis	1969
Functional obstructive cardiomyopathy	1973
Functional obstruction of the left ventricle	1957
Functional obstructive subvalvular aortic stenosis	1968
Functional subaortic stenosis	1960
Hereditary cardiovascular dysplasia	1961
Hypertrophic cardiomyopathy	1970
Hypertrophic constrictive cardiomyopathy	1972
Hypertrophic hyperkinetic cardiomyopathy	1965
Hypertrophic infundibular aortic stenosis	1971
Hypertrophic nonobstructive cardiomyopathy	1975
Hypertrophic obstructive cardiomyopathy	1964
Hypertrophic stenosing cardiomyopathy	1972
Hypertrophic subaortic stenosis	1962
Idiopathic hypertrophic cardiomyopathy	1972
Idiopathic hypertrophic obstructive cardiomyopathy	1966
Idiopathic hypertrophic subaortic stenosis	1960
Idiopathic hypertrophic subvalvular stenosis	1966
Idiopathic muscular hypertrophic subaortic stenosis	1966
Idiopathic muscular stenosis of the left ventricle	1969
Idiopathic myocardial hypertrophy	1963
Idiopathic stenosis of the flushing chamber of the left ventricle	1964
Idiopathic ventricular septal hypertrophy	1962
Irregular hypertrophic cardiomyopathy	1968
Left ventricular muscular stenosis	1968
Low subvalvular aortic stenosis	1962
Muscular aortic stenosis	1969
Muscular hypertrophic stenosis of the left ventricle	1966
Muscular stenosis of the left ventricle	1961
Muscular subaortic stenosis	1966
Muscular subvalvular aortic stenosis	1964
Non-dilated cardiomyopathy	1974
Nonobstructive hypertrophic cardiomyopathy	1975
Obstructive cardiomyopathy	1960
Obstructive hypertrophic aortic stenosis	1967
Obstructive hypertrophic cardiomyopathy	1968
Obstructive hypertrophic myocardiopathy	1968